Lilly Wins Second Accelerated Approval for Reversible BTK Inhibitor
Lilly’s Jaypirca (pirtobrutinib) can now be used to treat chronic lymphocytic leukemia or small lymphocytic leukemia that had progressed from at least two prior lines of therapy, in addition to its previously-approved indications.
Lilly Wins Second Accelerated Approval for Reversible BTK Inhibitor Read More »
